Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination
Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination
Graf Acquisition Corp. IV Withdraws Extension Proposal
Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021
Graf Acquisition Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering
Graf Acquisition Corp. IV Announces Closing of Underwriters’ Over-Allotment Option in Connection with its Initial Public Offering
Graf Acquisition Corp. IV Announces Closing of $150 Million Initial Public Offering